Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells.

Mitsuuchi Y, Benetatos CA, Deng Y, Haimowitz T, Beck SC, Arnone MR, Kapoor GS, Seipel ME, Chunduru SK, McKinlay MA, Begley CG, Condon SM.

Cell Death Discov. 2017 Jan 16;3:16046. doi: 10.1038/cddiscovery.2016.46. eCollection 2017.

2.

Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.

Walsh AM, Kapoor GS, Buonato JM, Mathew LK, Bi Y, Davuluri RV, Martinez-Lage M, Simon MC, O'Rourke DM, Lazzara MJ.

Mol Cancer Res. 2015 Aug;13(8):1227-37. doi: 10.1158/1541-7786.MCR-14-0183-T. Epub 2015 May 1.

3.

Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.

Condon SM, Mitsuuchi Y, Deng Y, LaPorte MG, Rippin SR, Haimowitz T, Alexander MD, Kumar PT, Hendi MS, Lee YH, Benetatos CA, Yu G, Kapoor GS, Neiman E, Seipel ME, Burns JM, Graham MA, McKinlay MA, Li X, Wang J, Shi Y, Feltham R, Bettjeman B, Cumming MH, Vince JE, Khan N, Silke J, Day CL, Chunduru SK.

J Med Chem. 2014 May 8;57(9):3666-77. doi: 10.1021/jm500176w. Epub 2014 Apr 15.

PMID:
24684347
4.

Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.

Benetatos CA, Mitsuuchi Y, Burns JM, Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, Laporte MG, Rippin SR, Deng Y, Hendi MS, Tirunahari PK, Lee YH, Haimowitz T, Alexander MD, Graham MA, Weng D, Shi Y, McKinlay MA, Chunduru SK.

Mol Cancer Ther. 2014 Apr;13(4):867-79. doi: 10.1158/1535-7163.MCT-13-0798. Epub 2014 Feb 21. Erratum in: Mol Cancer Ther. 2014 Sep;13(9):2246-7. Dosage error in article text.

5.

Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy.

Chawla S, Krejza J, Vossough A, Zhang Y, Kapoor GS, Wang S, O'Rourke DM, Melhem ER, Poptani H.

AJNR Am J Neuroradiol. 2013 Aug;34(8):1542-9. doi: 10.3174/ajnr.A3384. Epub 2013 Jan 31.

6.

Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.

Tykocinski ES, Grant RA, Kapoor GS, Krejza J, Bohman LE, Gocke TA, Chawla S, Halpern CH, Lopinto J, Melhem ER, O'Rourke DM.

Neuro Oncol. 2012 May;14(5):613-23. doi: 10.1093/neuonc/nos073. Epub 2012 Apr 4.

7.

IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB.

Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.

8.

SIRPalpha1 receptors interfere with the EGFRvIII signalosome to inhibit glioblastoma cell transformation and migration.

Kapoor GS, O'Rourke DM.

Oncogene. 2010 Jul 22;29(29):4130-44. doi: 10.1038/onc.2010.164. Epub 2010 May 17.

PMID:
20473329
9.

Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells.

Ayuso-Sacido A, Moliterno JA, Kratovac S, Kapoor GS, O'Rourke DM, Holland EC, García-Verdugo JM, Roy NS, Boockvar JA.

J Neurooncol. 2010 May;97(3):323-37. doi: 10.1007/s11060-009-0035-x. Epub 2009 Oct 24.

PMID:
19855928
10.

Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status.

Kapoor GS, Gocke TA, Chawla S, Whitmore RG, Nabavizadeh A, Krejza J, Lopinto J, Plaum J, Maloney-Wilensky E, Poptani H, Melhem ER, Judy KD, O'Rourke DM.

J Neurooncol. 2009 May;92(3):373-86. doi: 10.1007/s11060-009-9880-x. Epub 2009 Apr 9.

PMID:
19357963
11.

Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging.

Whitmore RG, Krejza J, Kapoor GS, Huse J, Woo JH, Bloom S, Lopinto J, Wolf RL, Judy K, Rosenfeld MR, Biegel JA, Melhem ER, O'Rourke DM.

J Neurosurg. 2007 Sep;107(3):600-9.

PMID:
17886561
12.

EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53.

Kapoor GS, Christie A, O'Rourke DM.

Cancer Biol Ther. 2007 Apr;6(4):571-9.

PMID:
17457042
13.
15.

Receptor tyrosine kinase signaling in gliomagenesis: pathobiology and therapeutic approaches.

Kapoor GS, O'Rourke DM.

Cancer Biol Ther. 2003 Jul-Aug;2(4):330-42. Review.

PMID:
14508101
16.

Mitogenic signaling cascades in glial tumors.

Kapoor GS, O'Rourke DM.

Neurosurgery. 2003 Jun;52(6):1425-34; discussion 1434-5. Review.

PMID:
12762887
17.

pp90RSK- and protein kinase C-dependent pathway regulates p42/44MAPK-induced LDL receptor transcription in HepG2 cells.

Kapoor GS, Golden C, Atkins B, Mehta KD.

J Lipid Res. 2003 Mar;44(3):584-93. Epub 2003 Jan 1.

18.
20.

Diagnostic efficacy of polymerase chain reaction in granulomatous uveitis.

Arora SK, Gupta V, Gupta A, Bambery P, Kapoor GS, Sehgal S.

Tuber Lung Dis. 1999;79(4):229-33.

PMID:
10692991
22.

Heterogeneity in heat shock protein genes in Leishmania isolates.

Arora SK, Kapoor GS, Sehgal S.

Immunol Cell Biol. 1998 Apr;76(2):186-9.

PMID:
9619490
23.
24.

A genetic analysis of HIV-1 from Punjab, India reveals the presence of multiple variants.

Jameel S, Zafrullah M, Ahmad M, Kapoor GS, Sehgal S.

AIDS. 1995 Jul;9(7):685-90.

PMID:
7546411

Supplemental Content

Loading ...
Support Center